Abstract | OBJECTIVE: To discuss the chemistry, pharmacokinetics, spectrum of activity, clinical trials, adverse effects, drug interactions, and dosage guidelines of cefpodoxime proxetil. DATA SOURCES: Literature was identified through a MEDLINE search from 1988 to the present and from review of bibliographies in that literature. STUDY SELECTION: Data were limited to comparative trials published in the English literature. Although many studies were conducted in Japan, the results often were available only in Japanese or partly in English. As these studies could not be completely evaluated, they are not included in this review. DATA SYNTHESIS: CONCLUSIONS:
Cefpodoxime demonstrates good in vitro activity against pathogens frequently associated with respiratory tract, urinary tract, and skin and tissue infections. It has not demonstrated greater efficacy than the other antibiotics to which it has been compared. The available published clinical trials are fraught with methodologic, statistical, and evaluative flaws. Thus, further trials comparing cefpodoxime with established treatments, as well as the newer cephalosporins, are needed before its place in therapy can be established.
|
Authors | E C Chocas, C M Paap, P J Godley |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 27
Issue 11
Pg. 1369-77
(Nov 1993)
ISSN: 1060-0280 [Print] United States |
PMID | 8286813
(Publication Type: Journal Article, Review)
|
Chemical References |
- cefpodoxime proxetil
- Ceftizoxime
|
Topics |
- Administration, Oral
- Age Factors
- Bacterial Infections
(drug therapy, microbiology)
- Ceftizoxime
(analogs & derivatives, pharmacokinetics, pharmacology, therapeutic use)
- Clinical Trials as Topic
- Drug Interactions
- Female
- Humans
- Male
- Otitis Media
(drug therapy)
- Respiratory Tract Infections
(drug therapy)
- Skin Diseases, Infectious
(drug therapy)
- Urinary Tract Infections
(drug therapy)
|